Related Experiment Video
Updated: Jul 11, 2025

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
[Severe systemic vasculitis induced by ibrutinib]
M Fenot1, P Woaye Hune2, S Vigouroux3
1Dermatologie, CHD Vendée, Les Oudairies, boulevard Stéphane-Moreau, 85925 La-Roche-sur-Yon, France.
Introduction:
The specific cutaneous toxicity of Bruton's tyrosine kinase inhibitors is poorly described. We report a case of severe systemic vasculitis induced by ibrutinib.
Observation:
A 73-year-old woman with chronic lymphocytic leukemia was treated with ibrutinib. Eighteen months after treatment onset, ulceronecrotic lesions on toes and tongue occurred. Skin biopsy found vasculitis of small and medium vessels. Biologic tests were negative. This vasculitis was refractory to systemic corticosteroid therapy and azathioprine. Ibrutinib was stopped on the hypothesis of drug-induced vasculitis. Skin lesions improved after discontinuation of ibrutinib.
Conclusion:
The mechanism of action of ibrutinib does not explain the occurrence of vasculitis and an immunoallergic mechanism is suspected.
More Related Videos
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Myocarditis III: Medical Management
Drugs for Treatment of Ulcerative Colitis in IBD
Vascular Spasm

